VBIV (VBI Vaccines, Inc.) Nilai Buku Perusahaan

Amidst fierce competition in the immuno-oncology segment and a capital deficit, VBI Vaccines Inc. (VBIV) is forced to seek strategic partners. This chart on GURU.Markets illustrates the price action of the asset, which is currently valued at -0.01. The business relies on unique VLP technology, creating a powerful defensive barrier in the form of a hepatitis B vaccine. Revenue is generated through drug sales and grant payments.

VBIV - Kapitalisasi Buku VBI Vaccines ing rentang 04.07.2022 - 17.08.2024

VBIV (VBI Vaccines Inc): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:

Bagan bursa VBI Vaccines Inc.|VBIV - Target konsensus

- indikator valuasi pasar bisnis:

Nilai pasar VBI Vaccines, Inc.|VBIV - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku Saham VBI Vaccines|VBIV - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku vbivaccines.com|VBIV - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal VBI Vaccines Inc.|VBIV - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal VBI Vaccines Inc.|VBIV - Utang perusahaan|Utang marang nilai buku VBI Vaccines, Inc.|VBIV - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan VBI Vaccines|Rasio jangkoan perantara vbivaccines.com

- statistik bathi lan rasio pasar:

VBIV - Penghasilan resik

Analisis wiwitan perusahaan:VBI Vaccines Inc.

Stable revenue from the commercialization of hepatitis B vaccines and patent protection provide VBI Vaccines Inc. (VBIV) with a solid foundation for asset growth. By analyzing capital dynamics via the balance sheet on GURU.Markets, an investor can identify the net asset value minus all liabilities, enabling a real-time assessment of the issuer's intrinsic value and minimizing risks during periods of high market volatility.

Analisis pesaing VBI Vaccines Inc.